GSK
StockTwit: Bio calendar (Feb 9) FDA approval decision date for $GSK and $XNPT Solzira: Bio calendar (Feb 9) FDA ap... http://bit.ly/dlOgWh
GSK
Bio calendar (Feb 9) FDA approval decision date for $GSK and $XNPT Solzira
GSK
RT @MaverickNY: $GSK announced growth in EM http://bit.ly/cL7ITA day after I posted this: new trends in Pharma http://bit.ly/9cdVk0
GSK
$GSK announced growth in EM http://bit.ly/cL7ITA day after I posted this: new trends in Pharma: Emerging Markets http://bit.ly/9cdVk0
GSK
rt @fortunemagazine GlaxoSmithKline $GSK 4Q profit up 66% thanks to swine flu vaccine. http://bit.ly/ciX7Rj
GSK
RT @reutersBenHir: Glaxo job cuts hit UK, Italy, Canada, Croatia, Poland http://ca.reuters.com/article/businessNews/idCATRE6141UF20100205 $G
GSK
Glaxo job cuts hit UK, Italy, Canada, Croatia, Poland http://ca.reuters.com/article/businessNews/idCATRE6141UF20100205 $GSK
GSK
rt @fortunemagazine GlaxoSmithKline $GSK 4Q profit up 66% thanks to swine flu vaccine. http://bit.ly/ciX7Rj: rt @... http://bit.ly/aUc7Ms
GSK
rt @fortunemagazine GlaxoSmithKline $GSK 4Q profit up 66% thanks to swine flu vaccine. http://bit.ly/ciX7Rj
GSK
Czech Republic May Cancel $GSK Swine Flu Vaccine Orders http://bit.ly/doEu7D [#news #emerging #europe]
GSK
GSK partnership with Xenoport at risk as $GSK sheds pain programs: http://bit.ly/9AZaHD
GSK
RT @lisamjarvis: Some detail on GlaxoSmithKline R&D cuts (including sites that are likely to be shuttered): http://bit.ly/aNkPRI $GSK
GSK
RT @MedAdNewsreal: RT @lisamjarvis: Some detail on GlaxoSmithKline R&D cuts (including sites that are likely to be shuttered): http://bi
GSK
RT @lisamjarvis: Some detail on GlaxoSmithKline R&D cuts (including sites that are likely to be shuttered): http://bit.ly/aNkPRI $GSK
GSK
RT @lisamjarvis: Some detail on GlaxoSmithKline R&D cuts (including sites that are likely to be shuttered): http://bit.ly/aNkPRI $GSK
GSK
Some detail on GlaxoSmithKline R&D cuts (including sites that are likely to be shuttered): http://bit.ly/aNkPRI $GSK
GSK
GlaxoSmithKline Shifts Focus from Antidepressants After Generics Hurt Sales ($GSK)
GSK
Fed up with depression? Glaxo CEO Witty is. Antidepressant research gets the axe in efficiency drive $GSK http://link.reuters.com/zex67h
GSK
$GSK aims for 14% return on late stage pipeline http://bit.ly/9U9o5K #pharma #stocks #cantos $$
GSK
RT @FortuneMagazine: GlaxoSmithKline $GSK 4Q profit up 66% thanks to swine flu vaccine. http://bit.ly/ciX7Rj
GSK
Genmab says that sales of Arzerra, the $100K cancer drug sold with $GSK, were $5 million in first quarter of sales.
GSK
GlaxoSmithKline $GSK 4Q profit up 66% thanks to swine flu vaccine. http://bit.ly/ciX7Rj
GSK
RT @mhuckman: Glaxo $GSK says it's seriously thinking about giving up on research in neuroscience, incl. depression and pain.
GSK
Uncrowded fields where small improvements can launch big RT mhuckman Glaxo $GSK pursues Alzheimer's and diseases MS, Parkinson's, etc.
GSK
RT @mhuckman: Glaxo $GSK would still pursue Alzheimer's and diseases like MS, Parkinson's, etc.
GSK
Ideas + capital = innovation. Phase 3-ready is the new word RT mhuckman $GSK "goal to increase externally sourced compounds in pipeli
GSK
@mhuckman $GSK CEO Andrew Witty interview and transcript on Q4 FY results http://bit.ly/9U9o5K #cantos #pharma #stocks $$
GSK
More partnership deals 4 Glaxo? $GSK "Our goal is to further
increase the level of externally sourced compounds in our pipeline."
GlaxoSmithKline PLC - GSK Insiders
No Insiders
We have no insiders for GlaxoSmithKline right now.
Know someone who is an insider on GlaxoSmithKline PLC?
Let us know.
GlaxoSmithKline PLC - GSK information
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health related consumer products. It operates in two segments, Pharmaceutical and Consumer Healthcare. The Pharmaceutical segment offers prescription medicines in the therapeutic areas, such as respiratory, central nervous system, anti-virals, anti-bacterials, metabolic, vaccines, cardiovascular and urogenital, oncology, emesis, and dermatology. This segment markets approximately 25 vaccines to prevent life-threatening or crippling illnesses, such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment offers OTC medicines, such as alli, a weight loss medicine; Panadol, a paracetamol/acetaminophen analgesic; smoking control products under the NicoDerm, NiQuitin CQ, Nicabate, and Nicorette names; and other brands, including Breathe Right nasal strips, Tums, Citrucel, Contac, and FiberChoice. Its oral healthcare products comprise Aquafresh, a range of toothpastes, toothbrushes, and mouthwashes; Sensodyne, a range of toothpastes and toothbrushes, including Pronamel to protect from acid erosion; Biotene, a treatment for dry mouth; Polident, PoliGrip, and Corega, the denture care cleansers and adhesives; and other brands, including Odol, Macleans, and Dr Best. This segment also provides nutritional healthcare products, such as Lucozade, a range of energy and sports drinks; Horlicks, a range of milk-based malted food and chocolate drinks; and Ribena, a blackcurrant juice-based drink. GlaxoSmithKline operates in the United States, Europe, Japan, the Asia Pacific, the Middle East, Latin America, Africa, and Canada. The company was founded in 1935 and is based in Brentford, the United Kingdom....
www.gsk.com
99,913 Employees
Founded in 1935
GLAXOSMITHKLINE PLC-SPON ADR (GSK:New York)
LAST $35.17 USD
CHANGE TODAY +0.01 0.03%
VOLUME 2.5M
As of 8:04 PM 07/30/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of GLAXOSMITHKLINE PLC-SPON ADR (GSK)
|
OPEN
$34.86
|
PREVIOUS CLOSE
$35.16
|
|
|
DAY HIGH
$35.40
|
DAY LOW
$34.85
|
|
|
52 WEEK HIGH
12/4/09 - $43.47
|
52 WEEK LOW
05/25/10 - $32.15
|
|
|
MARKET CAP
91.3B
|
AVERAGE VOLUME 10 D
2.5M
|
|
|
EPS TTM
--
|
SHARES OUTSTANDING
2.6B
|
|
|
EX-DATE
07/28/10
|
P/E TTM
--
|
|
|
DIVIDEND
$1.83
|
DIVIDEND YIELD
5.64%
|
|
| K = Thousands M = Millions B = Billions | ||
related news
*Sanofi-Aventis CEO Viehbacher at a glance
AP Digital - 07/30/2010 6:37 AM ET
Sanofi CEO targeting everything but blockbusters
AP Digital - 07/30/2010 6:34 AM ET
The Philadelphia Inquirer PhillyInc column: PhillyInc: GlaxoSmithKline changing incentives for sales force [The Philadelphia Inquirer]
The McClatchy Company - 07/28/2010 9:09 AM ET
Key developments for GLAXOSMITHKLINE PLC-SPON ADR (GSK)
GlaxoSmithKline plc Presents at 3rd Annual Global Biobanking 2010, Sep-29-2010 09:10 AM
07/27/2010
GlaxoSmithKline plc Presents at 3rd Annual Global Biobanking 2010, Sep-29-2010 09:10 AM. Venue: Thistle Marble Arch, London, Greater London, United Kingdom. Speakers: Laurie Overton, Manager, Fermentation Facility.
GlaxoSmithKline plc Presents at Clinical Trials MENA, Sep-26-2010 through Sep-29-2010
07/27/2010
GlaxoSmithKline plc Presents at Clinical Trials MENA, Sep-26-2010 through Sep-29-2010. Venue: Mvenpick Hotel, Jumeirah Beach, Dubai, United Arab Emirates. Presentation Date & Speakers: Sep-28-2010, Nada Riachi, Clinical Operations Manager, Pascal Fourmanoir, Cold Chain Manager.
GlaxoSmithKline Seeks Small Bolt-On Acquisitions; Reportedly Eyes Genzyme
07/26/2010
Andrew Witty, CEO of GlaxoSmithKline plc told La Tribune that the firm is hunting for small bolt-on acquisitions. He added, We may do small targeted deals, but nothing big. We will not do a large transaction in pharma nor in generics. GlaxoSmithKline made a very casual approach to Genzyme Corp., asking to be notified if Genzyme considered selling itself, the Wall Street Journal reported, citing a person familiar with the matter. There have been no further discussions between the two companies, the report added.
GSK Competitors
| Company | Last | Change |
| AstraZeneca PLC | 3,238 GBp | -51.00 |
| Bayer AG | €44.11 EUR | -0.39 |
| Reckitt Benckiser Group PLC | 3,125 GBp | -56.00 |
| Roche Holding AG | SFr.135.50 CHF | -0.80 |
| Unilever PLC | 1,811 GBp | -10.00 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | GSK | Industry Range |
| Price/Earnings | 100.0x |
|
| Price/Sales | 201.8x |
|
| Price/Book | 687.1x |
|
| Price/Cash Flow | 1,505.7x |
|
| TEV/Sales | 205.3x |
|
|
GSK |
||
|
GSK transactions
| Type Date |
Target |
|
Merger/Acquisition
July 1, 2010 |
GlaxoSmithKline plc, Operations at Medicines Research Centre in Verona |
|
Merger/Acquisition
May 28, 2010 |
GlaxoSmithKline Site in Dartford Town Centre |
|
Merger/Acquisition
May 11, 2010 |
Dong-a Pharmaceutical Co. Ltd. |
GlaxoSmithKline PLC - GSK news
UPDATE - Colgate, Glaxo sue over toothpaste "nurdle"
2010-07-30 02:35:54
Keywords: United States of America,Pharmaceuticals (sub-industry),Legislation,Judicial processes/court cases/court decisions,Retailing,Apparel retail,Personal products,Food products,Pharmaceuticals - diversified,United Kingdom,Western Europe,Europe,Advertising,Medi
Quote: Escalating a battle between two of the world's biggest
toothpaste makers, Colgate-Palmolive Co (CL.N) sued
GlaxoSmithKline Plc (GSK.L)(GSK.N) in Manhattan federal court,
seeking a court order that its packaging for Colgate toothpaste
does not infringe trademarks held by the maker of Aquafresh. A few hours later, Glaxo filed its own lawsuit against
Colgate in the same court, seeking to stop the infringement of
its own marks. Each company is seeking the right to depict, and to stop
the other from ...Read article
Defending Fish Oil, Criticizing Glaxo
2010-07-29 06:48:20
Keywords: Medicine, Pharmacuticals, Health Care, Drugs, Drug Companies, Hospitals, Health Insurance
Quote: Steven Salzberg wrote earlier this week about GlaxoSmithKline's marketing of fish oil, a supplement, as a drug in the form of its omega-3 fatty acid pill, Lovaza. I took issue with his post, because I think the data for the fish oil omega-3s, DHA and EPA, are pretty strong. (I've previously written about this here and here.) What follows is based on an email exchange we had.
Lovaza has been around a while. It was originally developed by ProNova Biopharma in Norway and marketed in Europe by Solva...Read article
GlaxoSmithKline to Implement New Compensation Program for U.S. Sales Professionals
2010-07-27 09:28:05
Keywords: GlaxoSmithKline to Implement New Compensation Program for U.S. Sales Professionals, gsk
Quote: healthcare marketplace is changing significantly in response to demand by patients, healthcare providers and payers for higher quality care, lower costs and better health outcomes," said Deirdre Connelly, President, North America Pharmaceuticals, GlaxoSmithKline. Â "Physicians have been telling us they want to see fewer sales professionals, and those they do see need to provide greater value in helping improve patient health. Â In response, we are changing the way we sell our medicines and v...Read article
GSK Apologizes Over Medical Journal Snafu
2010-07-27 09:28:04
Quote: By Peter Loftus
It must have seemed like a good idea at the time to the folks at GlaxoSmithKline: Pay a medical journal to run a special supplement about prostate cancer, which — surprise — included information about a Glaxo drug.
That’s what the UK drug maker did for the May 2009 edition of Urology, a peer-reviewed journal published by Elsevier. The supplement had articles by several doctors and included information about clinical testing of Glaxo’s drug Avodart in men at risk f...Read article
'Right Price' Will Get Genzyme Deal Done
2010-07-27 09:28:02
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Adam Feuerstein ,Drugs
Quote: GlaxoSmithKline(GSK) is thinking about kicking the tires, too. Genzyme is flattered by all the attention but the biotech firm isn't ready to commit just yet. Unless, of course, the asking price is rightSo, what is that "right" asking price for Genzyme? A good starting point is $80 a share, according to a source close to the situation.Genzyme would be worth well more than $80 a share if the company were better managed and wasn't saddled with smaller, money-losing drug franchises, but $80 a share ...Read article
FDA issues hold on much-debated Avandia study
2010-07-22 12:55:40
Keywords: FDA issues hold on much-debated Avandia study, gsk
Quote: WASHINGTON (AP) -- Federal health officials are barring new patients from enrolling in a safety study of GlaxoSmithKline's controversial diabetes pill Avandia, a week after a panel of experts ruled that the drug increases heart risks.The Food and Drug Administration said it issued a "partial clinical hold" on the study to update researchers on the latest concerns about Avandia, which has been under scrutiny since 2007.Last week a panel of experts voted that the drug appears to increase heart ris...Read article
UPDATE - US halts new enrollment in Glaxo's Avandia trial
2010-07-22 12:55:39
Keywords: Health and medicine,Pharmaceuticals (sub-industry),United States of America,Washington / US Government News,Regulation and enforcement,Biotechnology,Pharmaceuticals - diversified,United Kingdom,Western Europe,Europe,Pharmaceuticals - generic and specialit
Quote: health officials have
halted enrollment of new patients in a clinical trial of
GlaxoSmithKline Plc's (GSK.L) diabetes pill Avandia while
regulators consider if the drug should stay on the market. Diabetics already in the trial, known as Tide, may continue
to participate, the Food and Drug Administration said in a
statement on Wednesday. The FDA will update the public on the trial once it
completes a review of Avandia's risks, the agency said. An
advisory panel last week voted 20-12 that Avandia ...Read article
The Cancer-Causing Sex Virus
2010-07-22 12:55:39
Keywords: HPV, Oral Sex, Pap Smear, Cervical Cancer, Gardasil
Quote: Two vaccines, Gardasil from MerckMRKnewspeople) and Cervarix from GlaxoSmithKlineGSKnewspeople), are approved for preventing cervical cancer. Gardasil is approved for use in boys only to prevent genital warts. Vaccinating boys could stop this meteoric increase in throat cancer. "Clearly, boys need to be vaccinated," says Marshall Posner, the incoming medical director of head and neck cancer at Mt. Sinai Medical Center in New York. "I want my kids to be vaccinated. I don't see a downside to these...Read article
[$$] FDA Issues Hold on Avandia Study
2010-07-22 12:55:38
Quote: BY JENNIFER CORBETT DOORENAND ALICIA MUNDY WASHINGTON—The Food and Drug Administration ordered GlaxoSmithKline PLC to stop enrolling patients in a clinical trial of its troubled diabetes drug Avandia while the FDA weighs whether to pull the drug from the market. The trial, comparing Avandia to rival drug Actos from Takeda Pharmaceutical Co., has enrolled only about 1,100 patients of a targeted 16,000. "The study is effectively over," said David Nathan, a diabetes specialist at Massachuse...Read article
[$$] Charges, Restructuring Hit Glaxo Net
2010-07-22 12:55:38
Quote: BY JEANNE WHALEN The cost of settling legal disputes, including lawsuits over the diabetes drug Avandia, wiped out much of GlaxoSmithKline PLC's profit in the second quarter, as Glaxo's chief executive suggested that the company's future Avandia liability will be low. Glaxo took a charge of £1.57 billion ($2.4 billion) in the quarter to pay for the legal settlements, contributing to a net loss of £304 million, compared to net profit of £1.44 billion in the year-earlier quarter. Re...Read article
[$$] Two Health-Care Stocks That Are Priced Right
2010-07-21 03:21:41
Quote: But for European drug maker GlaxoSmithKline (ticker: GSK) and medical-products giant Baxter International (BAX), the FDA's unkind attentions could set the stage for attractive returns. Already hurt by a weak economy here and abroad, and by worries about the financial impact of health-care reform measures signed into law earlier this year, companies that make prescription drugs, medical equipment and other health-care products are facing increased scrutiny from regulators. And the FDA hasn't b...Read article
[$$] Glaxo Rival Paid Fees to Doctor Who Voted Against Avandia
2010-07-21 03:21:41
Quote: The statement by Abraham Thomas, head of the endocrinology and diabetes division at Henry Ford Hospital in Detroit, follows the disclosure Monday that another doctor on the panel, David Capuzzi of Philadelphia, is a paid speaker for the maker of Avandia, GlaxoSmithKline PLC. Dr. Capuzzi said in an interview that he hasn't given talks to doctors promoting Avandia but spoke on behalf of a different Glaxo drug. ......Read article
Pfizer - Upgrades & Downgrades
2010-07-20 06:02:08
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Kevin Baker ,TheStreet Ratings
Quote: In all, eight stocks were downgraded and two stocks have been upgraded by our stock model.One Friday, Pfizer announced that its entire pipeline of AIDS drugs associated with its joint venture partners ViiV Healthcare and GlaxoSmithKlineGSK) would be available to generic drugmakers of royalty-free production. This revenue trimming gesture was made in advance of the Vienna International AIDS conference and covers the 69 least developed countries including sub-Saharan Africa.The only stock upgraded...Read article
[$$] Panelist Who Backed Avandia Gets Fees From Glaxo
2010-07-20 06:02:04
Quote: BY ALICIA MUNDY WASHINGTON—One of the panelists who voted in favor of the diabetes drug Avandia at a Food and Drug Administration advisory meeting last week is a paid speaker for the drug's maker, GlaxoSmithKline PLC, according to the company and its records. The panel voted 20-12 to keep Avandia on the market, though most of the members wanted stronger warnings. Endocrinologist David Capuzzi of Philadelphia confirmed that he has been on Glaxo's speakers bureau for several years and sai...Read article
UPDATE - Don't dump Avandia, diabetes groups urge patients
2010-07-16 03:07:08
Keywords: Health and medicine,Science; technology,Pharmaceuticals (sub-industry),Regulation and enforcement,Insurance (industry group),Financials,Domestic Politics,United States of America,Washington / US Government News,Pharmaceuticals - diversified,United Kingdom
Quote: Food and Drug
Administration recommended, but with substantial divisions,
that GlaxoSmithKline's (GSK.L) (GSK.N) diabetes drug stay on
the market, despite worries that it may raise the risk of heart
attacks. [ID:nLDE66E07B] The experts agreed the drug, known generically as
rosiglitazone, raised concerns about heart risks but also
agreed it did not seem to raise the risk of death. The Endocrine Society, American Diabetes Association and
the American Association of Clinical Endocrinologists worrie...Read article
Glaxo gains on FDA nod for Avandia
2010-07-16 03:07:06
Keywords: Industries|Healthcare, GSK, GlaxoSmithKline PLC, 4502, Takeda Pharmaceutical Co Ltd
Quote: pharmaceutical giant GlaxoSmithKline PLC saw its shares move notably higher Thursday, the day after an advisory panel of the U.S. Food and Drug Administration voted to recommend the agency allow the company's controversial diabetes drug Avandia to stay on the market.Shares of Glaxo/quotes/comstock/13*!gsk/quotes/nls/gsk(GSK37.21,+0.86,+2.37%) were up 2% at $37.09.On Wednesday, a joint panel meeting of FDA advisors said that while they believe Avandia carries a higher risk of heart attack, it sho...Read article
The Death Of Avandia
2010-07-15 04:52:37
Keywords: Medicine, Pharmacuticals, Health Care, Drugs, Drug Companies, Hospitals, Health Insurance
Quote: Avandia, once the best-selling diabetes drug in the world, is set to become a heavily restricted niche product, plastered with scary warnings.
While the majority of a panel of experts told the Food and Drug Administration that GlaxoSmithKline's diabetes drug Avandia should remain on the market, they said it should have the most severe restrictions possible.
Several panelists blasted GlaxoSmithKline for not conducting better safety trials of its drug, forcing experts to grapple with uncertainty f...Read article
FDA panel: Diabetes drug should stay on market
2010-07-15 04:52:34
Keywords: FDA panel: Diabetes drug should stay on market, gsk
Quote: WASHINGTON (AP) -- GlaxoSmithKline's drug Avandia should stay on the market, federal health experts voted Wednesday, but the controversial diabetes pill should be subject to new restrictions due to risky heart side effects.A panel of Food and Drug Administration advisers voted 20-12 to keep the once blockbuster pill available for diabetics. But 10 panelists also called for limiting who can receive and prescribe the much-debated medication.The vote marks a tough win for British drugmaker Glaxo, w...Read article
UPDATE - US advisers: keep Glaxo's Avandia on the market
2010-07-15 04:52:34
Keywords: Health and medicine,Pharmaceuticals (sub-industry),United States of America,Washington / US Government News,Regulation and enforcement,Biotechnology,Pharmaceuticals - diversified,United Kingdom,Western Europe,Europe,Pharmaceuticals - generic and specialit
Quote: Wed Jul 14, 2010 8:08pm EDT
* 20 members of 33-strong panel vote to keep on mkt * Panel stance seen easing risk of further litigation * Avandia sales seen declining further * Critics still hope FDA will ban Avandia * Glaxo shares close 1.8 pct higher in New York(Adds panel member quotes, analyst on FDA flexibility) By Lisa Richwine and Susan Heavey GAITHERSBURG, Md, July 14 (Reuters) - GlaxoSmithKline Plc's
(GSK.L) diabetes drug Avandia should be allowed to stay on the
market but with additiona...Read article
GlaxoSmithKline to take $2.36 billion legal charge
2010-07-15 04:52:33
Keywords: , GSK, GlaxoSmithKline PLC, GSK, GlaxoSmithKline PLC
Quote: LONDON (MarketWatch) -- Drug company GlaxoSmithKline/quotes/comstock/23s!a:gsk(UK:GSK1,195,+13.00,+1.10%)/quotes/comstock/13*!gsk/quotes/nls/gsk(GSK36.35,+0.63,+1.76%) said Thursday that it will record a legal charge of 1.57 billion pounds ($2.36 billion) in the second quarter, which includes settlements, agreements in principle to settle and other provisioning for long-standing legal cases. The company said its agreed to pay 500 million pounds to settle an investigation by the U.S. government i...Read article